Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 26

Results For "Ltd"

857 News Found

Glenmark launches next phase of ‘India First Heart First’ campaign
Healthcare | May 17, 2024

Glenmark launches next phase of ‘India First Heart First’ campaign

35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases


Biocon posts Q4 FY24 PAT at Rs. 135 Cr
News | May 17, 2024

Biocon posts Q4 FY24 PAT at Rs. 135 Cr

EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%


Briefs: Lupin and Aurobindo Pharma
News | May 13, 2024

Briefs: Lupin and Aurobindo Pharma

Lupin updates on shipment of Mirabegron ER Tablets


Dr. Lal PathLabs posts Q4 FY24 consolidated PAT at Rs. 84.5 Cr
News | May 11, 2024

Dr. Lal PathLabs posts Q4 FY24 consolidated PAT at Rs. 84.5 Cr

The company has posted net profit of Rs.357.7 crores for the Financial Year ended March 31, 2024


Ami Organics posts Q4 FY24 consolidated profit at Rs. 25.14 Cr
News | May 11, 2024

Ami Organics posts Q4 FY24 consolidated profit at Rs. 25.14 Cr

Ami Organics has reported total income of Rs. 226.30 crores during the period ended March 31, 2024


Cipla receives 1 observation from USFDA for Kurkumbh facility
Drug Approval | May 10, 2024

Cipla receives 1 observation from USFDA for Kurkumbh facility

The company is committed to address this observation comprehensively within stipulated time


Vijaya Diagnostic Centre posts Q4 FY24 consolidated PAT at Rs. 33.45 Cr
News | May 09, 2024

Vijaya Diagnostic Centre posts Q4 FY24 consolidated PAT at Rs. 33.45 Cr

The company has posted net profit of Rs.118.82 crores for the Financial Year ended March 31, 2024


Dr. Reddy's Laboratories launches Doxycycline Capsules, 40 mg in US
Drug Approval | May 06, 2024

Dr. Reddy's Laboratories launches Doxycycline Capsules, 40 mg in US

ORACEA is a trademark of Galderma Holdings, S.A.


Briefs: Eugia Pharma Specialities and IOL Chemicals and Pharmaceuticals
Drug Approval | May 06, 2024

Briefs: Eugia Pharma Specialities and IOL Chemicals and Pharmaceuticals

Eugia Pharma Specialities receives 7 observations from USFDA for Unit II